The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 10, 2017

Filed:

Jan. 08, 2014
Applicants:

Novartis Ag, Basel, CH;

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Xizhong Huang, Cambridge, MA (US);

Jean J. Zhao, Brookline, MA (US);

Junxia Min, Cambridge, MA (US);

Yubao Wang, Newton, MA (US);

Assignees:

Novartis AG, Basel, CH;

Dana-Farber Cancer Institute, Inc., Boston, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); C12N 9/12 (2006.01); A61K 38/12 (2006.01); A61K 31/7088 (2006.01); C12Q 1/68 (2006.01);
U.S. Cl.
CPC ...
C12N 9/12 (2013.01); A61K 31/7088 (2013.01); A61K 38/12 (2013.01); C12N 15/1135 (2013.01); C12N 15/1137 (2013.01); C12Q 1/6886 (2013.01); C12Y 207/11001 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12Q 2600/158 (2013.01);
Abstract

Methods for inhibiting growth or proliferation of breast cancer cells are provided. The methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. In some aspects, the methods include administering to a subject in need thereof in an amount that is effective to inhibit growth or proliferation of the breast cancer cells a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor, wherein the breast cancer cells are estrogen receptor (ER) negative. Methods of treatment for breast cancer and methods of identifying patients having cancer that are likely to benefit from treatment with a MELK inhibitor, a FoxM1 inhibitor or a MELK inhibitor and a FoxM1 inhibitor are also provided.


Find Patent Forward Citations

Loading…